Skip to main content
SNY
NASDAQ Life Sciences

赛诺菲的Nuvaxovid COVID-19疫苗在头对头研究中表现出更好的耐受性

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$48.2
Mkt Cap
$116.306B
52W Low
$43.32
52W High
$55.73
Market data snapshot near publication time

summarizeSummary

赛诺菲宣布了一项头对头的4期研究的积极结果，显示其Nuvaxovid COVID-19疫苗的耐受性比Moderna的mNEXSPIKE有统计学意义上的改善。该研究发现Nuvaxovid导致系统性和局部反应原性降低，严重的系统性症状的频率降低了50%以上。这一改善的耐受性特征可以解决疫苗接种率低的主要原因，因此可能会提高Nuvaxovid在持续的COVID-19疫苗市场中的竞争地位。这一消息与赛诺菲最近公布的lunsekimig的积极的2期研究结果是不同的。交易者应该监测未来的销售数据，以评估这种耐受性优势是否转化为Nuvaxovid的市场份额增加。

在该公告发布时，SNY的交易价格为$48.20，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1163.1亿。 52周交易区间为$43.32至$55.73。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SNY - Latest Insights

SNY
Apr 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Prices €2.3 Billion Multi-Tranche Bond Issue for General Corporate Purposes
Sentiment: Neutral
View Wiseek Article
SNY
Apr 27, 2026, 12:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Secures Key FDA Approvals for Dupixent and Tzield, Despite Sarclisa Delay
Sentiment: Positive
View Wiseek Article
SNY
Apr 24, 2026, 6:09 AM EDT
Source: GlobeNewswire
Importance Score:
8
EU Regulators Recommend Sanofi's Cenrifki for Secondary Progressive MS Approval
Sentiment: Positive
View Wiseek Article
SNY
Apr 23, 2026, 7:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Strong Q1 Double-Digit Sales & EPS Growth, Multiple Regulatory Approvals, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
SNY
Apr 18, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability in Head-to-Head Study
Sentiment: Positive
View Wiseek Article
SNY
Apr 15, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Positive Phase 2 Lunsekimig Data and EU Approval for Dupixent in Young Children with CSU
Sentiment: Positive
View Wiseek Article
SNY
Apr 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Sanofi's Lunsekimig Meets Phase 2 Endpoints in Asthma and CRSwNP, Bolstering Respiratory Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 12:19 PM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Reports Positive Phase 3 Amlitelimab Data for Atopic Dermatitis, Advances Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Rezurock Secures EU Conditional Approval for Chronic Graft-vs-Host Disease
Sentiment: Positive
View Wiseek Article
SNY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
CHMP Recommends EU Approval for Sanofi's Innovative Sarclisa On-Body Injector for Multiple Myeloma
Sentiment: Positive
View Wiseek Article